专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019106187A1 ANTIGEN-BINDING MOLECULE FORMAT 审中-公开
公开(公告)号：WO2019106187A1
公开(公告)日：2019-06-06
申请号：PCT/EP2018/083224
申请日：2018-11-30
申请人： HUMMINGBIRD BIOSCIENCE HOLDINGS PTE. LTD. , CLEGG, Richard
发明人： BOYD-KIRKUP, Jerome , BRAUER, Peter , INGRAM, Piers , PASZKIEWICZ, Konrad , WU, Zhihao , GUAN, Siyu
IPC分类号： C07K16/46 , C07K14/725 , C07K16/28 , A61K47/68
CPC分类号： C07K16/468 , C07K14/7051 , C07K16/2803 , C07K2317/31 , C07K2317/51 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/60 , C07K2317/626 , C07K2317/64 , C07K2319/00 , C07K2319/30
摘要： Antigen-binding molecules comprising T cell receptor gamma chain constant region and delta chain constant region are disclosed. Also disclosed are nucleic acids and expression vector encoding, compositions comprising, and methods using the antigen-binding molecules.

2. 发明申请

WO2018187215A1 BISPECIFIC 4-1BB AGONIST MOLECULES 审中-公开
公开(公告)号：WO2018187215A1
公开(公告)日：2018-10-11
申请号：PCT/US2018/025700
申请日：2018-04-02
申请人： MERRIMACK PHARMACEUTICALS, INC.
发明人： RAUE, Klaus Andreas , TAM, Eric M.
IPC分类号： C07K19/00 , C07K16/46 , C07K16/28
CPC分类号： C07K16/2818 , A61K2039/505 , C07K16/2878 , C07K2317/31 , C07K2317/41 , C07K2317/526 , C07K2317/71 , C07K2317/75 , C07K2317/76 , C07K2319/00
摘要： Disclosed are bispecific molecules that comprise a 4-1BB agonist moiety connected to a CD8+ T-cell binding moiety and methods for using such bispecific molecules to treat 4-1BB-related disorders such as cancer.

3. 发明申请

WO2018069416A1 TRIPLE VECTOR FOR EXPRESSING ANTIBODY MOLECULES IN FULL THERAPEUTIC FORMAT 审中-公开
标题翻译：用于在完整治疗形式中表达抗体分子的三重载体
公开(公告)号：WO2018069416A1
公开(公告)日：2018-04-19
申请号：PCT/EP2017/075983
申请日：2017-10-11
申请人： ARGENX BVBA , FAIRJOURNEY BIOLOGICS
发明人： PAJUELO, Maria Gonzales , DE HAARD, Johannes Joseph Wilhelmus
IPC分类号： C12N15/63
CPC分类号： C07K16/005 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/569 , C12N15/63 , C12N15/86 , C12N2830/00 , C12N2840/00
摘要： A triple expression vector is disclosed for expressing an antibody molecule comprising an Fc domain in prokaryotic cells and in eukaryotic cells. The triple expression vector comprises a polynucleotide encoding an Fc domain; a polynucleotide encoding a phage coat protein; a cloning site for cloning genes encoding an antibody molecule or a part thereof wherein the antibody molecule or part thereof does not comprise an Fc domain; a prokaryotic secretion signal sequence and a eukaryotic secretion signal sequence, or a secretion signal sequence that drives efficient secretion in both prokaryotic and eukaryotic cells; a promoter for mediating expression in eukaryotic cells; and a stop codon for preventing expression of the phage coat protein in eukaryotic cells. The triple expression vector can be used for expressing an antibody molecule in a phage display format; for producing the antibody molecule in a prokaryotic cell, for example in the periplasm of a prokaryotic cell; and for producing the antibody molecule in a eukaryotic cell, for example a mammalian cell, more particularly a human cell. The antibody molecule contains an Fc domain, and may be for example a VHH-Fc molecule or an scFv-Fc molecule or a VH-Fc or a VL-Fc. Phage display libraries produced with the vector present the antibody molecule in its therapeutic format. Use of the vector avoids the need for repeated cloning when moving from one expression medium to another.
摘要翻译：公开了用于在原核细胞和真核细胞中表达包含Fc结构域的抗体分子的三重表达载体。三重表达载体包含编码Fc结构域的多核苷酸; 编码噬菌体外壳蛋白的多核苷酸; 克隆编码抗体分子或其部分的基因的克隆位点，其中抗体分子或其部分不包含Fc结构域; 原核分泌信号序列和真核分泌信号序列，或驱动原核细胞和真核细胞中有效分泌的分泌信号序列; 用于介导真核细胞中的表达的启动子; 和用于防止真核细胞中噬菌体外壳蛋白表达的终止密码子。三重表达载体可用于以噬菌体展示形式表达抗体分子; 用于在原核细胞中产生抗体分子，例如在原核细胞的周质中; 并且用于在真核细胞例如哺乳动物细胞，更特别是人细胞中产生抗体分子。抗体分子含有Fc结构域，并且可以是例如VHH-Fc分子或scFv-Fc分子或VH-Fc或VL-Fc。用载体产生的噬菌体展示文库以其治疗形式呈递抗体分子。使用载体避免了从一种表达载体移动到另一种载体时需要重复克隆。

4. 发明申请

WO2017114694A1 VARIABLE REGIONS FOR NKp46 BINDING PROTEINS 审中-公开
标题翻译： NKp46结合蛋白的可变区域
公开(公告)号：WO2017114694A1
公开(公告)日：2017-07-06
申请号：PCT/EP2016/081953
申请日：2016-12-20
申请人： INNATE PHARMA
发明人： GAUTHIER, Laurent , ANCERIZ, Nadia , MOREL, Ariane , ROSSI, Benjamin
IPC分类号： C07K16/28 , C07K16/18 , C07K16/46
CPC分类号： C07K16/2803 , C07K16/2809 , C07K16/2887 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/526 , C07K2317/622 , C07K2317/732 , C07K2317/92
摘要： NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
摘要翻译：提供了结合NKp46的免疫球蛋白可变区，以及包含可变区的蛋白质如抗体和多特异性蛋白质。蛋白质可以结合并特异性重定向NK细胞以裂解感兴趣的靶细胞。这些蛋白质可用于治疗疾病，特别是癌症或传染病。

5. 发明申请

WO2017072210A1 ANTI-VARIANT FC-REGION ANTIBODIES AND METHODS OF USE 审中-公开
标题翻译：抗变异FC区抗体和使用方法
公开(公告)号：WO2017072210A1
公开(公告)日：2017-05-04
申请号：PCT/EP2016/075884
申请日：2016-10-27
申请人： F. HOFFMANN-LA ROCHE AG , HOFFMANN-LA ROCHE INC.
发明人： KOWALEWSKY, Frank , RITTER, Mirko , STUBENRAUCH, Kay-Gunnar , WESSELS, Uwe
IPC分类号： C07K16/22 , C07K16/00 , G01N33/53 , G01N33/68 , C07K16/28 , C07K16/42
CPC分类号： C07K16/22 , C07K16/00 , C07K16/283 , C07K16/2854 , C07K16/2863 , C07K16/42 , C07K2317/524 , C07K2317/526
摘要： The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations I253A/H310A/H435A in the Fc-region, and methods of using the same.
摘要翻译：本发明提供了与Fc区中具有突变P329G或突变P329G / L234A / L235A或突变I253A / H310A / H435A的抗体特异性结合的抗变体Fc区抗体，以及使用它们的方法。

6. 发明申请

WO2017036905A1 MULTIMERIC PROTEINS WHICH BIND TO HUMAN FC-RECEPTORS 审中-公开
标题翻译：多种与人类受体结合的蛋白质
公开(公告)号：WO2017036905A1
公开(公告)日：2017-03-09
申请号：PCT/EP2016/070052
申请日：2016-08-25
申请人： UCB BIOPHARMA SPRL
发明人： HEYWOOD, Sam Philip , HUMPHREYS, David Paul
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： C07K16/00 , A61K2039/505 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/528 , C07K2317/53
摘要： The invention relates to multimeric proteins which bind to human Fc-receptors. The invention also relates to therapeutic compositions comprising the multimeric proteins, and their use in the treatment of immune and other disorders.
摘要翻译：本发明涉及结合人Fc受体的多聚体蛋白质。本发明还涉及包含多聚体蛋白质的治疗组合物及其在治疗免疫和其它疾病中的用途。

7. 发明申请

WO2017027422A1 CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOF 审中-公开
标题翻译：具有SIRP-ALPHA域或其变体的构造
公开(公告)号：WO2017027422A1
公开(公告)日：2017-02-16
申请号：PCT/US2016/045914
申请日：2016-08-05
申请人： ALEXO THERAPEUTICS INC.
发明人： PONS, Jaume , DEMING, Laura , GOODMAN, Corey , SIM, Bang Janet , KAUDER, Steven Elliot , WAN, Hong , KUO, Tracy Chia-Chien
IPC分类号： C07K14/47 , C07K14/705 , A61K38/17 , A61K39/395
CPC分类号： C07K14/70596 , A61K38/00 , A61K38/1709 , A61K38/177 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6811 , A61K2039/505 , C07K14/4703 , C07K14/70503 , C07K16/00 , C07K16/2803 , C07K16/2818 , C07K16/2863 , C07K2317/24 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30 , A61K2300/00
摘要： The present disclosure features signal-regulatory protein a (SIRP-α) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-α constructs include a high affinity SIRP-α D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-α. The SIRP-α polypeptides or constructs include a SIRP-α D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein a (SIRP- α) D1 variant and (ii) an antibody.
摘要翻译：本公开的特征在于信号调节蛋白a（SIRP-α）多肽和可用于例如靶向细胞（例如，癌细胞或免疫系统的细胞）的构建体，以增加靶细胞的吞噬作用，消除免疫细胞如调节性T细胞，杀死癌细胞，治疗受试者中的疾病（例如癌症）或其任何组合。 SIRP-α构建体包括以高亲和力比野生型SIRP-α结合CD47的高亲和力SIRP-αD1结构域或其变体。 SIRP-α多肽或构建体包括与Fc结构域单体，人血清白蛋白（HSA），白蛋白结合肽或聚乙二醇（PEG）聚合物融合的SIRP-α1D变体。本文提供的组合物包括（i）包含信号调节蛋白a（SIRP-α）D1变体和（ii）抗体的多肽。

8. 发明申请

WO2017020001A2 HEAVY CHAIN ONLY ANTIBODIES TO ANG-2 审中-公开
标题翻译： ANG-2的重链抗体
公开(公告)号：WO2017020001A2
公开(公告)日：2017-02-02
申请号：PCT/US2016/044838
申请日：2016-07-29
申请人： ALLERGAN, INC.
发明人： LIANG, Yanbin , GIL, Daniel W.
IPC分类号： C07K16/22
CPC分类号： C07K16/22 , C07K2317/24 , C07K2317/33 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/64 , C07K2317/76 , C07K2317/92
摘要： Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.
摘要翻译：本文公开了对ANG-2具有抗原结合特异性的单特异性HCAb抗体和对ANG-2和VEGF或PDGF具有抗原结合特异性的双特异性抗体。

9. 发明申请

WO2016203432A1 ANTIBODY DRUG CONJUGATES 审中-公开
标题翻译：抗体药物联合用药
公开(公告)号：WO2016203432A1
公开(公告)日：2016-12-22
申请号：PCT/IB2016/053595
申请日：2016-06-17
申请人： NOVARTIS AG , ABRAMS, Tinya , COHEN, Steven , D'ALESSIO, Joseph Anthony , DAMIANO, Jason , DURR, Clemens , GEIERSTANGER, Bernhard Hubert , HU, Qi-Ying , HUBER, Thomas , IMASE, Hidetomo , JIN, Yunho , MENEZES, Daniel , MILLER, Kathy , MOHSENI, Morvarid , OU, Weijia , RENDAHL, Katherine , UNO, Tetsuo , WAN, Yongqin , WANG, Xing
发明人： ABRAMS, Tinya , COHEN, Steven , D'ALESSIO, Joseph Anthony , DAMIANO, Jason , DURR, Clemens , GEIERSTANGER, Bernhard Hubert , HU, Qi-Ying , HUBER, Thomas , IMASE, Hidetomo , JIN, Yunho , MENEZES, Daniel , MILLER, Kathy , MOHSENI, Morvarid , OU, Weijia , RENDAHL, Katherine , UNO, Tetsuo , WAN, Yongqin , WANG, Xing
IPC分类号： C07K16/28 , A61K47/48 , A61K31/00 , A61K39/395 , A61P35/00
CPC分类号： C07K16/28 , A61K45/06 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
摘要翻译：本申请公开了抗P-钙粘蛋白抗体，其抗原结合片段和所述抗体或抗原结合片段的抗体药物偶联物，特别是抗体药物偶联物，其包含缀合于奥司他丁类似物的抗P-钙粘蛋白抗体。本发明还涉及使用抗体药物偶联物治疗癌症的方法。本文还公开了制备抗体，抗原结合片段和抗体药物缀合物的方法，以及使用抗体和抗原结合片段作为诊断试剂的方法。

10. 发明申请

WO2016182751A1 HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS 审中-公开
标题翻译：异嗜性抗体结合CD3和肿瘤抗原
公开(公告)号：WO2016182751A1
公开(公告)日：2016-11-17
申请号：PCT/US2016/029797
申请日：2016-04-28
申请人： XENCOR, INC.
发明人： MOORE, Gregory , DESLARLAIS, John , BERNETT, Matthew , CHU, Seung , RASHID, Rumana , MUCHHAL, Umesh , LEE, Sung-Hyung
IPC分类号： A61K39/00 , C07K16/28 , C07K16/30 , C07K16/46
CPC分类号： C07K16/2809 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/526 , C07K2317/528 , C07K2317/55 , C07K2317/60 , C07K2317/622 , C07K2317/73 , C07K2317/92
摘要： The present invention is directed to novel heterodimeric antibodies.
摘要翻译：本发明涉及新的异二聚体抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式